Omiloxetine

Omiloxetine
Systematic (IUPAC) name
2-[(3R,4S)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-piperidinyl]-1-(4-fluorophenyl)ethanone
Identifiers
CAS Number 176894-09-0
ATC code None
PubChem CID 3047803
ChemSpider 2310120
UNII H8YI0SSF7B
ChEMBL CHEMBL2105290
Chemical data
Formula C27H25F2NO4
Molar mass 465.489 g/mol
Physical data
Density 1.3±0.1 g/cm3
Melting point 228.65 °C (443.57 °F)
Boiling point 587.2 °C (1,089.0 °F)
Solubility in water 0.0015 mg/mL (20 °C)

Omiloxetine (omiloextinum, omiloxetino INN)[1]:212-213 was a selective serotonin reuptake inhibitor drug candidate that underwent preclinical development by the Spanish pharmaceutical company, Ferrer Internacional, until 2005, when it was abandoned.[2][3]

References

  1. WHO Drug Information, Vol. 10, No. 4, 1996 Proposed INN: List 76
  2. Terencio, Jose (2005-12-05). "Omiloxetine - Ferrer licensing offer, worldwide". R & D Focus Drug News. Retrieved 2012-05-19.
  3. De Lecea, Dr Carlos (2003-12-08). "Omiloxetine - Ferrer partnering opportunity, worldwide Ferrer preclinical data". R & D Focus Drug News. Retrieved 2012-05-19.


This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.